Fingolimod impairs inactivated vaccine (CoronaVac)-induced antibody response to SARS-CoV-2 spike protein in persons with multiple sclerosis

BACKGROUND: : The impact of disease-modifying treatments on humoral response induced by inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines is understudied. METHODS: : We recruited 34 persons with multiple sclerosis (MS) under fingolimod treatment and 25 healthy individ...

Descripción completa

Detalles Bibliográficos
Autores principales: Türkoğlu, Recai, Baliç, Nesrin, Kızılay, Tuğçe, Erol, Ruziye, Akbayır, Ece, Yılmaz, Vuslat, Tüzün, Erdem
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2022
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8747775/
https://www.ncbi.nlm.nih.gov/pubmed/35033838
http://dx.doi.org/10.1016/j.msard.2022.103524
Descripción
Sumario:BACKGROUND: : The impact of disease-modifying treatments on humoral response induced by inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines is understudied. METHODS: : We recruited 34 persons with multiple sclerosis (MS) under fingolimod treatment and 25 healthy individuals. Anti-SARS-CoV-2 spike IgG indices were measured by ELISA in sera of participants after CoronaVac vaccinations. RESULTS: : Persons with MS displayed significantly lower antibody levels and seropositivity prevalence. Persons with MS with longer fingolimod treatment durations displayed lower anti-SARS-CoV-2 indices. CONCLUSION: : Our results support previous findings regarding humoral response impairing effect of fingolimod after vaccinations. Patients under fingolimod treatment may require closer monitoring for COVID-19.

Ejemplares similares